Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-29 @ 7:38 PM
Study NCT ID:
NCT05803694
Status:
COMPLETED
Last Update Posted:
2023-11-24
First Post:
2023-03-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ABL90 FLEX PLUS Clinical Precision Study for ctBil and FHbF Parameters in Neonatal Whole Blood
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Samples are collected to measure the ctBil and FHbF parameters in neonatal whole blood. Samples are destroyed when measurements are completed.'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 54}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-03-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-12', 'completionDateStruct': {'date': '2023-09-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-22', 'studyFirstSubmitDate': '2023-03-25', 'studyFirstSubmitQcDate': '2023-03-25', 'lastUpdatePostDateStruct': {'date': '2023-11-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-04-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-07-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'ABL90 FLEX PLUS Clinical Precision', 'timeFrame': '5 hours', 'description': 'Repeatability (SD) for each parameter (ctBil and FHbF), parameter level and measuring mode, pooled across sites.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Blood Tests']}, 'descriptionModule': {'briefSummary': 'Conducting the ABL90 FLEX PLUS Clinical Precision Study for ctBil and FHbF Parameters in Neonatal Whole Blood is to validate performance claims for precision of the ABL90 FLEX PLUS ctBil and FHbF parameters in neonatal whole blood while being influenced by testing environment that is representative of intended use environment, site variability, intended use testing environment and operator variability in a Point-of-Care (POC) setting.\n\nThe investigational device is the ABL90 FLEX PLUS incl. consumables, running SW3.5 MR2, manufactured by Radiometer Medical ApS.\n\nThe study is being conducted in Denmark and in total, a minimum of 54 subjects are to be enrolled to provide successful measurement values from 3 different sites.', 'detailedDescription': 'The conduct of the clinical study is to determine the repeatability of ctBil and FHbF parameters in neonatal whole blood using contrived fetal cord blood from umbilical cord/placenta measured by the intended users in syringe, short probe, and capillary modes available for ABL90 FLEX PLUS, in a POC setting.\n\nThe primary endpoint is the Repeatability (SD) for each parameter, parameter level and measuring mode, pooled across sites.\n\nParticipating sites are maternity wards or similar site conducting planned cesarean sections. Pregnant women 18 years of age or older admitted to the maternity ward to undergo cesarian section after week 38 of gestation will be enrolled in the clinical study. When the subject has signed ICF, the site will collect cord blood from umbilical cord/placenta and when relevant prepare contrived samples by having access to adult type 0 Rh neg whole blood for diluting HbF in cord blood.\n\nThree POC users, such as a nurse, a physician, or a therapist that care for the woman in the maternity ward will perform all measurements and they shall contribute evenly to the total number of samples measured. Replicate measurements shall be performed by the same user.\n\n6-10 mL of cord blood is collected in a blood collection syringe from each umbilical cord/placenta, contrived, and the sample is aliquoted into 5 safePICO aspirators (max volume 1.5 mL) or into 25 capillary tubes.\n\nAt each site, samples will be collected for the 2 parameters, 3 modes and 3 levels, completing measurements from minimum of 18 samples from 18 subjects.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'genderBased': True, 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Pregnant women 18 years of age or older admitted to the maternity ward to undergo cesarian section after week 38 of gestation.', 'genderDescription': 'Pregnant women.', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pregnant women 18 years of age or older admitted to the maternity ward to undergo cesarian section.\n* Informed consent collected from subject able to understand information given, and willing and able to voluntarily give their consent to participate in this study.\n* Subject evaluated by the principal investigator or designee as suitable for the study according to the protocol.\n\nExclusion Criteria:\n\n* Subjects with known infectious disease such as Hepatitis C or HIV (to ensure the operator safety).'}, 'identificationModule': {'nctId': 'NCT05803694', 'briefTitle': 'ABL90 FLEX PLUS Clinical Precision Study for ctBil and FHbF Parameters in Neonatal Whole Blood', 'organization': {'class': 'INDUSTRY', 'fullName': 'Radiometer Medical ApS'}, 'officialTitle': 'ABL90 FLEX PLUS Clinical Precision Study for ctBil and FHbF Parameters in Neonatal Whole Blood', 'orgStudyIdInfo': {'id': 'DC-084471'}, 'secondaryIdInfos': [{'id': '22003', 'type': 'OTHER', 'domain': 'Radiometer'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'ABL90 FLEX PLUS analyser running SW3.5 MR2.', 'type': 'DEVICE', 'description': 'The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '2700', 'city': 'Copenhagen', 'state': 'Brønshøj', 'country': 'Denmark', 'facility': 'Radiometer Medical', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '3400', 'city': 'Hillerød', 'country': 'Denmark', 'facility': 'Ellen Løkkegaard', 'geoPoint': {'lat': 55.92791, 'lon': 12.30081}}]}, 'ipdSharingStatementModule': {'infoTypes': ['CSR'], 'timeFrame': 'January 2025', 'ipdSharing': 'YES', 'description': 'When the Clinical Study Report has been finalized, Data result will be available for public on platforms and in articles.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Radiometer Medical ApS', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}